Particle.news

Lunai Bioworks Regains Nasdaq Compliance as Shares Spike

Nasdaq’s Hearings Panel found the company met the $1.00 minimum bid-price rule, triggering a one-year monitoring period that preserves the risk of immediate delisting if the price falls again.

Overview

  • On June 11, the Nasdaq Hearings Panel notified Lunai that it satisfied the $1.00 minimum bid-price requirement and the conditions in extension letters dated April 20 and May 12, a fact the company disclosed in an SEC filing.
  • The SEC filing drove trading moves with LNAI up about 9% in the regular session and surging 80.88% to $5.15 in after-hours trading while volume jumped to roughly 19.33 million shares, about 33.4 times its daily average.
  • Restored compliance immediately begins a mandatory one-year Nasdaq panel monitoring period that allows Nasdaq to issue a delisting determination if the stock falls below $1.00, although Lunai may request a new Nasdaq hearing to pause any suspension or delisting action.
  • Despite the rally, the stock has fallen roughly 90% over the past 12 months, trades close to its 52-week low, and carries a market capitalization of about $12.9 million, all of which underscore ongoing structural weakness and investor risk.
  • Investors should watch price and volume over the monitoring year because a renewed slide under $1.00 would prompt delisting procedures and could produce further heavy trading and potential losses for shareholders.